Fanny Angelot‐Delettre

Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients

Arthur E. Frankel, Jung Hee Woo, Chul Ahn et al. · Blood · 2014 · 230 citations · Full text

Life Sciences, Immunology, Oncology +14

How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?

Francine Garnache‐Ottou, Chrystelle Vidal, Sabeha Biichlé et al. · Blood Advances · 2019 · 121 citations · Full text

Medicine, Hematology, Oncology +17

Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape

Loria Zalmaï, Pierre‐Julien Viailly, Sabeha Biichlé et al. · Haematologica · 2020 · 77 citations · Full text

Medicine, Hematology, Oncology +17

LXR agonist treatment of blastic plasmacytoid dendritic cell neoplasm restores cholesterol efflux and triggers apoptosis

Adam Ceroi, David Masson, Anne Roggy et al. · Blood · 2016 · 64 citations · Full text

Medicine, Oncology, Pharmacology +14

In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent

Fanny Angelot‐Delettre, Anne Roggy, Arthur E. Frankel et al. · Haematologica · 2014 · 63 citations · Full text

Medicine, Oncology, Pharmacology +11